display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR-positive - 1st line (L1)la/mBC - HR-positive - 2nd line (L2)
abemaciclib based treatment
abemaciclib plus aromatase inhibitor MONARCH 3
abemaciclib plus endocrine therapy MonarchE
abemaciclib plus fulvestrant MONARCH 2

Study type: